View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
The FDA has been informed of two additional deaths following medical abortion with mifepristone (Mifeprex) and is investigating the circumstances associated with the cases. The agency is making all providers of medical abortions aware of the specific circumstances and directions for use of this drug and all risks, including sepsis, when considering treatment.
In particular, providers and patients should fully discuss early signs and symptoms that may warrant immediate medical evaluation.
The approved regimen for mifepristone for a medical abortion through 49 days pregnancy is specified in the advisory along with information about sepsis and its symptoms.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top